Matches in Wikidata for { <http://www.wikidata.org/entity/Q89154305> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q89154305 description "clinical trial" @default.
- Q89154305 description "ensayu clínicu" @default.
- Q89154305 description "klinisch onderzoek" @default.
- Q89154305 description "клінічне випробування" @default.
- Q89154305 description "կլինիկական փորձարկում" @default.
- Q89154305 name "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection." @default.
- Q89154305 name "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection." @default.
- Q89154305 type Item @default.
- Q89154305 label "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection." @default.
- Q89154305 label "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection." @default.
- Q89154305 prefLabel "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection." @default.
- Q89154305 prefLabel "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection." @default.
- Q89154305 P1132 Q89154305-D726FBE6-0454-4E4E-88C1-61B22004B693 @default.
- Q89154305 P1476 Q89154305-857CD7E7-1C89-4F67-8650-FBADE8F368F4 @default.
- Q89154305 P17 Q89154305-3FBC7B6D-2135-4945-B9A7-08CC55B270E8 @default.
- Q89154305 P2899 Q89154305-41E78B18-88B6-4E29-A8E1-135F202E4D05 @default.
- Q89154305 P3098 Q89154305-EB09CE5E-1F8D-461D-839B-82ECC3D8936C @default.
- Q89154305 P31 Q89154305-31AC2B60-E168-4977-B972-D7AF2CECF545 @default.
- Q89154305 P4135 Q89154305-BD570E96-BDAD-4A07-9C70-E057EB54E819 @default.
- Q89154305 P4844 Q89154305-29B38771-4D60-4182-86B8-B0BFB3A7056A @default.
- Q89154305 P580 Q89154305-D8145206-1FA1-4A07-858A-14FAE00D636D @default.
- Q89154305 P582 Q89154305-E2F93335-283D-4EC6-AC4D-A7FC9B68C9E8 @default.
- Q89154305 P6099 Q89154305-78F09391-CC9C-479A-899B-DE2C72EEFF26 @default.
- Q89154305 P6099 Q89154305-D2F77383-0727-452B-88CC-6B3834D4FEBD @default.
- Q89154305 P8363 Q89154305-EDAF4067-750A-408C-B2DD-141C0971125D @default.
- Q89154305 P921 Q89154305-1C803E79-0833-4962-90C1-3E4EA7B4BA9D @default.
- Q89154305 P1132 "+54" @default.
- Q89154305 P1476 "A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection." @default.
- Q89154305 P17 Q38 @default.
- Q89154305 P2899 "+30" @default.
- Q89154305 P3098 "NCT04324021" @default.
- Q89154305 P31 Q30612 @default.
- Q89154305 P4135 "+79" @default.
- Q89154305 P4844 Q415411 @default.
- Q89154305 P580 "2020-03-01T00:00:00Z" @default.
- Q89154305 P582 "2020-07-01T00:00:00Z" @default.
- Q89154305 P6099 Q42824440 @default.
- Q89154305 P6099 Q42824827 @default.
- Q89154305 P8363 Q78089383 @default.
- Q89154305 P921 Q82069695 @default.